ReportsnReports

Biologics Industry Growth in BRIC to Outpace Traditional Pharma Markets

 
Repost This

Dallas, TX -- (SBWIRE) -- 06/15/2012 -- GBI Research, a leading business intelligence provider, has released its latest research Biological Strategies in the Emerging Markets BRIC Countries Will Underpin Future Pharma Growth which examines two major trends already impacting on marketing strategies in the global pharmaceutical environment. These trends are the rise in importance of biologic products as replacements for the traditional small-molecule drugs in pharmaceutical pipelines, and the emergence of new national markets driven by seismic shifts now taking place among the leading national markets in the global economy. The report discusses the strategies the industry needs to embrace to address these internal and external challenges.

GBI Research analysis highlights the trends in the biologic sector, with their impact on the therapy of a wide range of diseases, and the routes taken by companies to improve their presence in the biologic sector and maximize their product lifecycle management to ensure future growth and shareholder value.

The report offers a thorough analysis of the newly-emerging national markets, including not only the leading BRIC economies but also those economies dubbed “fast followers”. In an evolving market environment where an increasing proportion of products currently in late stage clinical development in pharmaceutical companies are biologics, this report discusses the opportunities for building success on these novel approaches in those markets which are set to feature prominently among the top national economies in the very near future.

Scope
1. The report describes major classes of biologic medicines, with their therapeutic applications and importance.
2. Significant pipeline developments now in advanced clinical trials are identified.
3. Major companies already present in the biologic arena are profiled.
4. The BRIC markets (Brazil, Russia, India and China) are described in detail, covering their importance as pharmaceutical markets.
5. Relevant background for each country, including healthcare provision, pricing and government policies towards foreign companies, is provided.
6. A general country analysis for each is also included, covering political, economic, social, technological, legislative and environmental aspects.
7. Four other “pharmerging” economies are also discussed in some detail.
8. Trends of importance to pharma market planners are discussed, as well as strategies important to foreign companies seeking a foothold in these markets.

Reasons to buy

1. Identify the key market opportunities with specific reference to the growth of biologics, so that you can align R&D portfolios to maximize growth
2. Develop optimal business strategies on a country-by-country basis, taking account of national market drivers and restraints
3. Devise a tailored R&D approach to address specific geographical and therapeutic demands
4. Develop key strategic initiatives based on your company’s pharma R&D strengths and their best deployment in a changing pharmaceutical world
5. Re-evaluate and reassess investment decisions and explore ways in which to diversify and optimise market penetration vis-à-vis the pharmerging economies.

Buy your copy of this report @ http://www.reportsnreports.com/reports/164925-biological-strategies-in-the-emerging-markets-bric-countries-will-underpin-future-pharma-growth.html . Contact sales@reportsandreports.com for further information.

List of Tables

Table 1: Biological Strategies in the Emerging Markets, Leading Cancer MAbs, 2011
Table 2: Biological Strategies in the Emerging Markets, Leading Approved Cytokines, 2010
Table 3: Biological Strategies in the Emerging Markets, Brazil, Core Statistics, 2010
Table 4: Biological Strategies in the Emerging Markets, Brazil, Foreign Investments, 2010
Table 5: Biological Strategies in the Emerging Markets, Russia, Core Statistics, 2010
Table 6: Biological Strategies in the Emerging Markets, Russia, Foreign Investments, 2010
Table 7: Biological Strategies in the Emerging Markets, India, Core Statistics
Table 8: Biological Strategies in the Emerging Markets, China, Core Statistics, 2010
Table 9: Biological Strategies in the Emerging Markets, China, Foreign Investments, 2010
Table 10: Biological Strategies in the Emerging Markets, Pharmaceutical Market and Biological Sector ($bn), 2010-2015
Table 11: Biological Strategies in the Emerging Markets, Russia, Most Harmful Diseases, 2010
Table 12: Biological Strategies in the Emerging Markets, Brazil, PESTLE Analysis Summary, 2010
Table 13: Biological Strategies in the Emerging Markets, Russia, PESTLE Analysis Summary, 2010
Table 14: Biological Strategies in the Emerging Markets, Russia, PESTLE Analysis Summary, 2010
Table 15: Biological Strategies in the Emerging Markets, China, PESTLE Analysis Summary, 2010
Table 16: Biological Strategies in the Emerging Markets, Brazil, Recognized Drug Classes, 2010
Table 17: Biological Strategies in the Emerging Markets, BRIC Nations, Pharmaceutical Expenditure By Payer, 2009
Table 18: Biological Strategies in the Emerging Markets, Global, Contribution of Pharmaceutical Market Growth, 2005, 2008, 2013
Table 19: Biological Strategies in the Emerging Markets, Global, Number of New General Drugs in Development, 2010
Table 20: Biological Strategies in the Emerging Markets, Global Therapeutic Biologics Pipeline (%), 2010
Table 21: Biological Strategies in the Emerging Markets, Leading Therapeutics Proteins in Clinical Development Worldwide to Treat Cancer, 2011
Table 22: Biological Strategies in the Emerging Markets, Leading Therapeutics Proteins in Clinical Development Worldwide to Treat Cancer, 2011
Table 23: Biological Strategies in the Emerging Markets, Leading Diabetes Molecules in Clinical Development Worldwide to Treat Cancer, 2011
Table 24: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Hormonal Conditions, 2011
Table 25: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Hemopoietic Conditions, 2011
Table 26: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Immuno-inflammatory Diseases, 2011
Table 27: Biological Strategies in the Emerging Markets, Leading Biologics Sales ($bn), 2010
Table 28: Biological Strategies in the Emerging Markets, Sales of Roche’s Leading Biologics ($bn), 2010
Table 29: Biological Strategies in the Emerging Markets, Sales of Novo’s Leading Biologics ($bn), 2010
Table 30: Biological Strategies in the Emerging Markets, Sales of J&J’s Leading Biologics ($bn), 2010
Table 31: Biological Strategies in the Emerging Markets, Sales of Sanofi’s Leading Biologics ($bn), 2010
Table 32: Biological Strategies in the Emerging Markets ,Sales of Lilly’s Leading Biologics ($bn), 2010
Table 33: Biological Strategies in the Emerging Markets, Sales of Sandoz’s Leading Biologics ($bn), 2010
Table 34: Biological Strategies in the Emerging Markets, Sales of Teva’s Leading Biologics ($bn), 2010
Table 35: Biological Strategies in the Emerging Markets , Recent Acquisitions in the Biologics Arena, 2011
Table 36: Biological Strategies in the Emerging Markets, Russia, Strategic Alliances, 2011
Table 37: Biological Strategies in the Emerging Markets, India, Strategic Alliances, 2011

List of Figures

Figure 1: Biological Strategies in the Emerging Markets, Global MAbs Therapeutic Sales Based on Prescription Usage, 2010
Figure 2: Biological Strategies in the Emerging Markets, Global , Market Share of Therapeutic Proteins (%), 2010
Figure 3: Biological Strategies in the Emerging Markets, China, Factors Stimulating Pharmaceutical Sales Growth, 2010
Figure 4: Biological Strategies in the Emerging Markets, Leading Chinese Companies with a Commitment to Developing R&D-Based Products, 2010
Figure 5: Biological Strategies in the Emerging Markets, BRIC Nations, Pharmaceutical Expenditure By Payer (%), 2009
Figure 6: Biological Strategies in the Emerging Markets, Global, Contribution of Pharmaceutical Market Growth (%), 2005, 2008, 2013
Figure 7: Biological Strategies in the Emerging Markets, Global Therapeutic Biologics Pipeline (%), 2010
Figure 8: Biological Strategies in the Emerging Markets, the US, Products in Development to Treat Cancer, 2010
Figure 9: Biological Strategies in the Emerging Markets, Important Factors for Launching Biologics, 2011